A Phase II Study of Weekly Docetaxel (Taxotere®) in Combination With Capecitabine (Xeloda) in Advanced Gastric and Gastro-Esophageal Adenocarcinomas.
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Overall Survival
研究概览
简要总结
This is a phase II study that will investigate weekly dosing of docetaxel in combination with capecitabine in advanced gastric and gastro-esophageal adenocarcinomas.
详细描述
This is a phase II study that will investigate weekly dosing of docetaxel in combination with capecitabine in advanced gastric and gastro-esophageal adenocarcinomas. Docetaxel 30mg/m2 will be administered on days 1 and 8 of each cycle and capecitabine 825mg/m2 bid (total daily dose 1650mg/m2) will be administered orally for 14 days (days 1-14) of each cycle. Each cycle is 21 days. Subjects will receive unlimited cycles of docetaxel and capecitabine until there is evidence of disease progression or unacceptable side effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have histologically or cytologically confirmed locally advanced (unresectable) or metastatic adenocarcinoma of gastric, gastro-esophageal, or esophageal origin.
- •Must have measurable or evaluable disease.
- •Received adjuvant therapy are eligible if adjuvant therapy was given ≥ 6 months prior to the diagnosis of metastatic disease.
- •Life expectancy greater than 12 weeks.
- •ECOG performance status <
- •Adequate organ and marrow function.
- •Preexisting peripheral neuropathy if present must be grade 0 or
- •Women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 3 months thereafter. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential
排除标准
- •No chemotherapy or radiotherapy within 4 weeks
- •Not receiving any other investigational agents or participate in any investigational drug study within 4 weeks preceding the start of study treatment.
- •Patients with known brain metastases shall be excluded from this clinical trial
- •Patients with evidence or history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant that precludes informed consent or interferes with the compliance of oral drug intake will also be excluded.
- •History of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel, capecitabine or 5-FU.
- •Uncontrolled intercurrent illness
- •Pregnant or breast feeding women are excluded from this study
- •Inability to swallow tablets or those who have malabsorptive symptoms will be excluded.
- •HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with docetaxel or capecitabine.
- •Prior use of docetaxel or capecitabine is not allowed ( Prior 5FU therapy is allowed).
- •Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cervical cancer.
- •Major surgery ( i.e laparotomy, line placement is not considered major surgery)within 4 weeks of the start of study treatment, without complete recovery.
- •Known, existing uncontrolled coagulopathy.
- •Patients on anticonvulsants that are metabolized via P450 3A4 pathway.
研究组 & 干预措施
Docetaxel + Capecitabine
Docetaxel 30mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days. Premedication with dexamethasone will be given to all patients receiving weekly docetaxel therapy to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. Cycle 2 will begin on day 22.
Capecitabine Capecitabine 825mg/m2 bid (total daily dose 1650mg/m2) will be administered orally for 14 days (days 1-14).
Each cycle will consist of 21 days. Cycle 2 will begin on day 22.
干预措施: Docetaxel (Drug)
Docetaxel + Capecitabine
Docetaxel 30mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days. Premedication with dexamethasone will be given to all patients receiving weekly docetaxel therapy to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. Cycle 2 will begin on day 22.
Capecitabine Capecitabine 825mg/m2 bid (total daily dose 1650mg/m2) will be administered orally for 14 days (days 1-14).
Each cycle will consist of 21 days. Cycle 2 will begin on day 22.
干预措施: Capecitabine (Drug)
结局指标
主要结局
Overall Survival
时间窗: 2 years
The time interval between the date on which a patient first received protocol treatment and the documented date of death.
次要结局
- Overall Response Rate(Every 2 cycles (6 weeks))
研究者
Nathan Bahary, MD
Associate Professor, Department of Medicine, Division of Oncology
University of Pittsburgh